Conferring alloantigen specificity to regulatory T cells: A comparative analysis of cell preparations undergoing clinical development in transplantation

dc.contributor.authorKurt, Ada Sera
dc.contributor.authorRuiz, Paula
dc.contributor.authorLandmann, Emmanuelle
dc.contributor.authorElgosbi, Marwa
dc.contributor.authorFung, Tsz Kan
dc.contributor.authorKodela, Elisavet
dc.contributor.authorLondoño, María Carlota
dc.contributor.authorMarin Correa, Diana
dc.contributor.authorPerpiñán, Elena
dc.contributor.authorLombardi, Giovanna
dc.contributor.authorSafinia, Niloufar
dc.contributor.authorMartinez Llordella, Marc
dc.contributor.authorSanchez Fueyo, Alberto
dc.date.accessioned2026-09-04T11:00:04Z
dc.date.available2026-09-04T11:00:04Z
dc.date.issued2024-09-19
dc.date.updated2026-08-21T11:55:36Z
dc.description.abstractConferring alloantigen-specificity to ex vivo expanded CD4+CD25+FOXP3 regulatory T cells (Tregs) increases their capacity to counteract effector alloimmune responses following adoptive transfer into transplant recipients. Three strategies are currently undergoing clinical development, which involve the following: (1) expanding Tregs in the presence of donor B cells (donor alloantigen-reactive [DAR] Tregs); (2) culturing Tregs with donor cells in the presence of costimulation blockade (CSB-Tregs); and (3) transducing Tregs with an human leukocyte antigen A2-specific chimeric antigen receptor (CAR-Tregs). Our goal in this study was to assess the relative potency of each of these manufactured Treg products both in vitro and in vivo. When compared with polyclonal Tregs, all 3 manufacturing strategies increased the precursor frequency of alloreactive Tregs, and this was proportional to the overall in vitro immunosuppressive properties of the cell products. Accordingly, CARTregs, which contained the highest frequency of donor-reactive Tregs, exhibited the strongest suppressive effects on a cell-per-cell basis. Similarly, in an in vivo mouse model of graft-vs-host disease, infusion of CAR-Tregs conferred a significantly longer recipient survival than any other Treg product. Our results highlighting the alloantigen-reactivity and associated immunosuppressive properties of different manufactured Treg products have implications for the mechanistic interpretation of currently ongoing clinical trials in transplantation.
dc.format.extent10
dc.format.mimetypeapplication/pdf
dc.identifier.idimarina9457108
dc.identifier.issn1600-6143
dc.identifier.pmid39299674
dc.identifier.urihttps://hdl.handle.net/2445/231281
dc.language.isoEnglish
dc.publisherElsevier Inc.
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1016/j.ajt.2024.09.009
dc.relation.ispartofAmerican Journal of Transplantation, 2025, vol. 25, num.1, p. 38-47
dc.relation.urihttps://doi.org/10.1016/j.ajt.2024.09.009
dc.rightscc by (c) Kurt, Ada Sera et al., 2024
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceArticles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)
dc.subject.classificationCèl·lules T
dc.subject.classificationImmunologia de la trasplantació
dc.subject.classificationEmpelts de teixits
dc.subject.otherT cells
dc.subject.otherTransplantation immunology
dc.subject.otherTissue transplantation
dc.titleConferring alloantigen specificity to regulatory T cells: A comparative analysis of cell preparations undergoing clinical development in transplantation
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
Conferring alloantigen specificity to regulatory T cells....pdf
Mida:
1.54 MB
Format:
Adobe Portable Document Format